Literature DB >> 10588735

Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.

H H Li1, W H Yu, N Rozengurt, H Z Zhao, K M Lyons, S Anagnostaras, M S Fanselow, K Suzuki, M T Vanier, E F Neufeld.   

Abstract

The Sanfilippo syndrome type B is an autosomal recessive disorder caused by mutation in the gene (NAGLU) encoding alpha-N-acetylglucosaminidase, a lysosomal enzyme required for the stepwise degradation of heparan sulfate. The most serious manifestations are profound mental retardation, intractable behavior problems, and death in the second decade. To generate a model for studies of pathophysiology and of potential therapy, we disrupted exon 6 of Naglu, the homologous mouse gene. Naglu-/- mice were healthy and fertile while young and could survive for 8-12 mo. They were totally deficient in alpha-N-acetylglucosaminidase and had massive accumulation of heparan sulfate in liver and kidney as well as secondary changes in activity of several other lysosomal enzymes in liver and brain and elevation of gangliosides G(M2) and G(M3) in brain. Vacuolation was seen in many cells, including macrophages, epithelial cells, and neurons, and became more prominent with age. Although most vacuoles contained finely granular material characteristic of glycosaminoglycan accumulation, large pleiomorphic inclusions were seen in some neurons and pericytes in the brain. Abnormal hypoactive behavior was manifested by 4.5-mo-old Naglu-/- mice in an open field test; the hyperactivity that is characteristic of affected children was not observed even in younger mice. In a Pavlovian fear conditioning test, the 4.5-mo-old mutant mice showed normal response to context, indicating intact hippocampal-dependent learning, but reduced response to a conditioning tone, perhaps attributable to hearing impairment. The phenotype of the alpha-N-acetylglucosaminidase-deficient mice is sufficiently similar to that of patients with the Sanfilippo syndrome type B to make these mice a good model for study of pathophysiology and for development of therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588735      PMCID: PMC24466          DOI: 10.1073/pnas.96.25.14505

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Drastically abnormal gluco- and galactosylceramide composition does not affect ganglioside metabolism in the brain of mice deficient in galactosylceramide synthase.

Authors:  K Suzuki; M T Vanier; T Coetzee; B Popko
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 2.  Mannose receptor.

Authors:  S E Pontow; V Kery; P D Stahl
Journal:  Int Rev Cytol       Date:  1992

3.  Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids.

Authors:  N Fujita; K Suzuki; M T Vanier; B Popko; N Maeda; A Klein; M Henseler; K Sandhoff; H Nakayasu; K Suzuki
Journal:  Hum Mol Genet       Date:  1996-06       Impact factor: 6.150

4.  Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B).

Authors:  B Weber; L Blanch; P R Clements; H S Scott; J J Hopwood
Journal:  Hum Mol Genet       Date:  1996-06       Impact factor: 6.150

Review 5.  Management of mucopolysaccharidosis type III.

Authors:  M A Cleary; J E Wraith
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

6.  Gene targeting in embryonic stem cells.

Authors:  R Ramírez-Solis; A C Davis; A Bradley
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

7.  Molecular dissection of a cosmid from a gene-rich region in 17q21 and characterization of a candidate gene for alpha-N-acetylglucosaminidase with two cDNA isoforms.

Authors:  Z Zhao; A Yazdani; Y Shen; Z Sun; J Bailey; C T Caskey; C C Lee
Journal:  Mamm Genome       Date:  1996-09       Impact factor: 2.957

8.  Enzyme replacement therapy for murine mucopolysaccharidosis type VII.

Authors:  M S Sands; C Vogler; J W Kyle; J H Grubb; B Levy; N Galvin; W S Sly; E H Birkenmeier
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.

Authors:  K Sango; S Yamanaka; A Hoffmann; Y Okuda; A Grinberg; H Westphal; M P McDonald; J N Crawley; K Sandhoff; K Suzuki; R L Proia
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

10.  Simultaneous preparation and quantitation of proteoglycans by precipitation with alcian blue.

Authors:  S Björnsson
Journal:  Anal Biochem       Date:  1993-05-01       Impact factor: 3.365

View more
  82 in total

1.  Storage vesicles in neurons are related to Golgi complex alterations in mucopolysaccharidosis IIIB.

Authors:  Sandrine Vitry; Julie Bruyère; Michaël Hocquemiller; Stéphanie Bigou; Jérôme Ausseil; Marie-Anne Colle; Marie-Christine Prévost; Jean Michel Heard
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

Authors:  Coy D Heldermon; Kevin K Ohlemiller; Erik D Herzog; Carole Vogler; Elizabeth Qin; David F Wozniak; Yun Tan; John L Orrock; Mark S Sands
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.

Authors:  Albert Ruzo; Miquel Garcia; Albert Ribera; Pilar Villacampa; Virginia Haurigot; Sara Marcó; Eduard Ayuso; Xavier M Anguela; Carles Roca; Judith Agudo; David Ramos; Jesús Ruberte; Fatima Bosch
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

4.  Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.

Authors:  Haiyan Fu; Aaron S Meadows; Tierra Ware; Robert P Mohney; Douglas M McCarty
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

5.  Mechanism of shortened bones in mucopolysaccharidosis VII.

Authors:  Jason A Metcalf; Yanming Zhang; Matthew J Hilton; Fanxin Long; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2009-03-25       Impact factor: 4.797

6.  Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.

Authors:  Shih-Hsin Kan; Mika Aoyagi-Scharber; Steven Q Le; Jon Vincelette; Kazuhiro Ohmi; Sherry Bullens; Daniel J Wendt; Terri M Christianson; Pascale M N Tiger; Jillian R Brown; Roger Lawrence; Bryan K Yip; John Holtzinger; Anil Bagri; Danielle Crippen-Harmon; Kristen N Vondrak; Zhi Chen; Chuck M Hague; Josh C Woloszynek; Diana S Cheung; Katherine A Webster; Evan G Adintori; Melanie J Lo; Wesley Wong; Paul A Fitzpatrick; Jonathan H LeBowitz; Brett E Crawford; Stuart Bunting; Patricia I Dickson; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

7.  A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.

Authors:  N M Ellinwood; P Wang; T Skeen; N J H Sharp; M Cesta; S Decker; N J Edwards; I Bublot; J N Thompson; W Bush; E Hardam; M E Haskins; U Giger
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).

Authors:  A R Garcia; J Pan; J C Lamsa; J Muenzer
Journal:  J Inherit Metab Dis       Date:  2007-09-16       Impact factor: 4.982

9.  Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB.

Authors:  Kazuhiro Ohmi; David S Greenberg; Kavitha S Rajavel; Sergey Ryazantsev; Hong Hua Li; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

10.  Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response.

Authors:  Smruti Killedar; Julianne Dirosario; Erin Divers; Phillip G Popovich; Douglas M McCarty; Haiyan Fu
Journal:  J Neuroinflammation       Date:  2010-07-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.